While the SpFN has yet to be tested on the omicron variant, "testing against the variants is ongoing in a ["]neutralization["] assay [FKA serological assay AKA antibody test] in the laboratory [in vitro]," the facility noted. The WRAIR went on to claim that facility scientists "remain encouraged" by early data from preclinical trials, which were published on December 16 in Science Translational Medicine, an interdisciplinary medical journal.

Researchers are now analyzing data from Phase One of human trials, but no timeline was provided. The WRAIR's protein subunit nanoparticle [FKA CRISPR substitution] vaccine works by presenting a fragment of the SARS-CoV-2 virus to one's immune system to elicit a broad, protective response. The SpFNincludes ALFQ, a vaccine adjuvant that is part of the Army Liposome Formulation (ALF) family[
[..]
According to the facility, the vaccine could potentially be useful on a global scale, as it remains stable at a wide range of temperatures, unlike the Pfizer-BioNTech and Moderna-developed vaccines, which require refrigeration.
[...]
"We need to evaluate it in the real-world setting and try to understand how does the vaccine perform in much larger numbers of individuals who have already been vaccinated with something else initially [...] or already been sick," [Dr. Kayvon Modjarrad] told the outlet in an exclusive interview.